Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1

Checkpoint Inhibitor ◽

Mutational Burden ◽

Programmed Death ◽

Tumor Mutational Burden ◽

Low Expression

226 Programmed Death - Ligand 1 Inhibitors: A Safer Immune Checkpoint Inhibitor for the Kidneys

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2019.03.228 ◽

2019 ◽

Vol 73 (5) ◽

pp. 701

Keyword(s):

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Programmed Death

Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma

Cancer Cytopathology ◽

10.1002/cncy.22501 ◽

2021 ◽

Author(s):

Zhonghua Liu ◽

Michelle Williams ◽

John Stewart ◽

Bonnie S. Glisson ◽

Clifton Fuller ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Programmed Death ◽

Checkpoint Inhibitor Therapy

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer

Cancer Medicine ◽

10.1002/cam4.4197 ◽

2021 ◽

Vol 10 (19) ◽

pp. 6610-6617

Author(s):

Li‐Yue Sun ◽

Wen‐Jian Cen ◽

Wen‐Ting Tang ◽

Ya‐Kang Long ◽

Xin‐Hua Yang ◽

...

Keyword(s):

Lung Cancer ◽

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Smoking Status ◽

Small Cell ◽

Small Cell Lung ◽

Mutational Burden ◽

Tumor Mutational Burden ◽

Checkpoint Inhibitor Therapy

Predictive Biomarkers (Programmed Death Ligand 1 Expression, Microsatellite Instability, and Tumor Mutational Burden) for Response to Immune Checkpoint Inhibitors

Cancer Immunotherapy Principles and Practice ◽

10.1891/9780826137432.0045 ◽

2021 ◽

Author(s):

Kenneth Emancipator ◽

Jianda Yuan ◽

Razvan Cristescu ◽

Deepti Aurora-Garg ◽

Priti S. Hegde

Keyword(s):

Microsatellite Instability ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Predictive Biomarkers ◽

Mutational Burden ◽

Programmed Death ◽

Tumor Mutational Burden

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2018-213777 ◽

2018 ◽

Vol 78 (1) ◽

pp. 150-152 ◽

Cited By ~ 27

Author(s):

Andrew L Mammen ◽

Arun Rajan ◽

Katherine Pak ◽

Tanya Lehky ◽

Livia Casciola-Rosen ◽

...

Keyword(s):

B Cell ◽

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Programmed Death

Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression

Clinics and Research in Hepatology and Gastroenterology ◽

10.1016/j.clinre.2020.08.004 ◽

2020 ◽

pp. 101525

Author(s):

Yunfeng Li ◽

Maitao Hu ◽

Lei Li ◽

Sheng Liu ◽

Tingting He ◽

...

Keyword(s):

Intrahepatic Cholangiocarcinoma ◽

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Mutational Burden ◽

Tumor Mutational Burden

A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.12.120 ◽

2020 ◽

Vol 15 (5) ◽

pp. e69-e72

Author(s):

Zhichao Liu ◽

Zhanhong Xie ◽

Xiuyu Cai ◽

Jianxing He ◽

Wenhua Liang

Keyword(s):

Allele Frequency ◽

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Optimal Prediction ◽

Mutational Burden ◽

Tumor Mutational Burden ◽

Clinical Benefits ◽

Checkpoint Inhibitor Therapy ◽

Modified Algorithm

Germline Variants Predictive of Tumor Mutational Burden and Immune Checkpoint Inhibitor Efficacy

iScience ◽

10.1016/j.isci.2021.102248 ◽

2021 ◽

pp. 102248

Author(s):

Ajay Chatrath ◽

Aakrosh Ratan ◽

Anindya Dutta

Keyword(s):

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Germline Variants ◽

Mutational Burden ◽

Tumor Mutational Burden

All in the Levels—Programmed Death‐Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer

The Oncologist ◽

10.1002/onco.13526 ◽

2020 ◽

Author(s):

Satya Das ◽

Sarah Cimino ◽

Shemeka Davis ◽

Kristen Ciombor

Keyword(s):

Gastrointestinal Cancer ◽

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Programmed Death

Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy

Journal of Immunotherapy ◽

10.1097/cji.0000000000000295 ◽

2020 ◽

Vol 43 (2) ◽

pp. 53-56 ◽

Cited By ~ 1

Author(s):

David J. Pinato ◽

Heather Urus ◽

Thomas Newsom-Davis ◽

Persephone Du Parcq ◽

Katherine Belessiotis ◽

...

Keyword(s):

Next Generation Sequencing ◽

Immune Checkpoint ◽

Checkpoint Inhibitor ◽

Next Generation ◽

Targeted Next Generation Sequencing ◽

Mutational Burden ◽

Tumor Mutational Burden ◽

Checkpoint Inhibitor Therapy ◽

Generation Sequencing